MedPage Today -- Most patients with resistant rheumatoid arthritis who failed to respond to an initial cycle of rituximab (Rituxan) showed clinical improvement following a second treatment cycle, a British study found.
MedPage Today -- Most patients with resistant rheumatoid arthritis who failed to respond to an initial cycle of rituximab (Rituxan) showed clinical improvement following a second treatment cycle, a British study found.
